Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

PZ0006

Sigma-Aldrich

Exemestane

≥98% (HPLC)

Synonyme(s) :

6-Methyleneandrosta-1,4-diene-3,17-dione

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H24O2
Numéro CAS:
107868-30-4
Poids moléculaire :
296.40
Numéro MDL:
MFCD00866994
Code UNSPSC :
51111800
ID de substance PubChem :
329823675
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D +250 to +300°, c = 1 in methanol

Couleur

white to off-white

Solubilité

DMSO: ≥20 mg/mL

Température de stockage

2-8°C

Chaîne SMILES 

C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O

InChI

1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1

Clé InChI

BFYIZQONLCFLEV-DAELLWKTSA-N

Informations sur le gène

human ... CYP19A1(1588)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Actions biochimiques/physiologiques

Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.

Caractéristiques et avantages

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictogrammes

Health hazardEnvironment
GHS08,GHS09

Mention d'avertissement

Danger

Mentions de danger

H360,H411

Classification des risques

Aquatic Chronic 2 - Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Willemien van de Water et al.
The oncologist, 18(1), 8-13 (2012-12-25)
For postmenopausal patients with hormone-sensitive breast cancer, outcome is worse with increasing age at diagnosis. The aim of this study was to assess the incidence of breast cancer recurrence (locoregional and distant), and contralateral breast cancer by age at diagnosis.
Willemien van de Water et al.
European journal of cancer (Oxford, England : 1990), 49(2), 297-304 (2012-09-08)
Multiple studies suggest better efficacy of chemotherapy in invasive ductal breast carcinomas (IDC) than invasive lobular breast carcinomas (ILC). However, data on efficacy of adjuvant endocrine therapy regimens and histological subtypes are sparse. This study assessed endocrine therapy efficacy in
Nan Soon Wong et al.
Expert opinion on pharmacotherapy, 6(13), 2353-2363 (2005-10-13)
Breast cancer is a major health problem in developed countries. Endocrine therapy is a key component in the management of hormone receptor-positive disease. Although tamoxifen has historically been the gold standard in the first-line management of early and advanced breast
John M S Bartlett et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(36), 4477-4484 (2012-10-10)
Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers
John Fr Robertson et al.
The Lancet. Oncology, 14(3), 228-235 (2013-02-19)
Insulin-like growth factors (IGF-1 and IGF-2) bind to the IGF-1 receptor (IGF-1R), increasing cell proliferation and survival. Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. We tested the efficacy and safety of adding ganitumab to endocrine treatment for patients
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique